Biotechnology firm Immunic Inc (NASDAQ:IMUX) announced the appointment of Simona Skerjanec to its board of directors.
Skerjanec brings nearly three decades of experience in drug development and commercialization, having held senior roles at top pharmaceutical companies.
Most recently, she was senior vice president, global head neuroscience and rare diseases at Roche, where she achieved significant sales growth with Ocrevus, a leading treatment for multiple sclerosis (MS). She also serves on the Board of Directors of Avidity Biosciences.
Immunic is a biotechnology firm developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases.
"We are thrilled to add someone of Simona's exceptional caliber and expertise to our Board of Directors," Immunic chairman Duane Nash said in a statement.
"As the company approaches multiple late-stage readouts for vidofludimus calcium in MS over the next two years, we are determined to continue building a strong foundation for potential success.”
Skerjanec expressed her excitement about joining Immunic’s board, stating: "MS remains a devastating disease for many patients and their families. In my view, vidofludimus calcium is a particularly valuable oral drug candidate, with a highly differentiated profile and the potential to transform the treatment landscape and bring longer lasting independence to people with MS.”
The appointment follows the recent addition of Jason Tardio, a former Novartis and Biogen executive, as Immunic's new chief operating officer and president, highlighting the company's commitment to building a strong leadership team as it advances its clinical pipeline.